Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securiti
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Calif., Dec. 14 Vermillion, Inc. ... today announced William C. Wallen, Ph.D. Chief ... Development for IDEXX Laboratories, will be joining ... Vermillion,s bankruptcy plan. ,, "Bill brings ... experience in diagnostics and biotechnology," said Gail ...
(Date:12/14/2009)... The third edition of ... published by the Infusion Nurses Society (INS), ... extravasation.(1) Anthracyclines are a group of chemotherapy ... have been used in the treatment of various ... ,, According to the INS publication: "In ...
(Date:12/14/2009)... SAN CARLOS, Calif., Dec. 14 Nektar ... Dennis Winger has been appointed to serve on ... highly-respected biopharmaceutical industry leader with over 35 years ... strategy. ,, "Dennis brings to Nektar extensive industry ... evolution," said Howard W. Robin, President and CEO ...
(Date:12/14/2009)... - Results From a Survey Conducted ... Seven Major Industrialized Countries , , - ... disease, impacts their enjoyment of ... rheumatoid arthritis find shopping for gifts, ... difficult to do, ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4
... Mass., Feb. 17 Idenix Pharmaceuticals, Inc. (Nasdaq: ... development of drugs for the treatment of human viral and ... fourth quarter and year ended December 31, 2008. At December ... $46.1 million. Business Highlights , , ...
... TechniKrom, Inc. and Asahi Kasei,Medical Co., Ltd., who ... for use with Planova(TM) virus removal filters,have reached ... Asahi Kasei Medical,s full ownership. The integration of,operations ... Kasei TechniKrom, Inc., a,wholly owned subsidiary of Asahi ...
... Inc., a biotechnology company delivering breakthrough therapies in ... is a SILVER level sponsor of the 2009 ... conference, put on by the Alzheimer,s Association, is ... 2009 will take place July 11-16 in Vienna, ...
Other Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7TechniKrom's Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical 2Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference 2
(Date:12/15/2009)... available in German ., Despite the ... the globe, cultures vary as to how space is ... use egocentric terms such as ,left, right, front, back, ... like ,north, south, east, west, at all times for ... or "There is an snake by your Northern leg". ...
(Date:12/15/2009)... near future, consumers can look forward to ultra-low ... laptops, PDAs and mobile phones. This is made ... technologies which are critical elements for power optimisation ... systems. , Analog IC design is the key ... To pre-position the nation in advanced analog and ...
(Date:12/15/2009)... Va., Dec. 15 The PTR Group, a ... announced that it has agreed to sponsor three high ... FIRST Robotics Competition ( http://usfirst.org ). ,, ... school teams in three different states. The teams ... Rockwall, TX, and James Madison HS in Vienna, VA ...
Breaking Biology News(10 mins):More than a jump to the left 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Study Details Swine Flu Transmission Rates 55637 1Study Details Swine Flu Transmission Rates 55637 2Study Details Swine Flu Transmission Rates 55637 3America Needs More Physician Hospitals 55635 1America Needs More Physician Hospitals 55635 2New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 1New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 2
... National Human Genome Research Institute (NHGRI), part of the ... identified six more genetic variants involved in type 2 ... risk factors associated with increased risk of the disease. ... study had previously been suspected of playing a role ...
... ANN ARBOR, Mich.---Scientists have identified six new genes which play ... among the group is the second gene known to also ... bring the total number of genes or genomic regions implicated ... in the Department of Biostatistics. Researchers from the University of ...
... that can be applied in the study of other ... in collaboration with colleagues at the University of Washington ... have identified multiple, individually rare gene mutations in people ... illness is caused. , The team screened ...
Other Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3Potential association of type 2 diabetes genes with prostate cancer 2CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 2CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 3
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
... preps Storage: The kit is stable for 12 ... all contents of the kit cold. , ... a silica-gel based membrane which selectively adsorbs up ... of specialized binding buffers. Nucleotides, oligos ( , ...
The Sony UPD895 printer is used to print data captured with the Gel Doc XR and ChemiDoc XRS gel documentation systems as well as the VersaDoc imaging systems....
Biology Products: